Pegaspargase
Pegaspargase
Definition
A complex of polyethylene glycol conjugated with L-asparaginase. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle. The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)
Also known as (Monomethoxypolyethylene Glycol Succinimidyl)74-L-Asparaginase, L-Asparaginase with Polyethylene Glycol, Oncaspar, Oncaspar-IV, PEG-Asparaginase, PEG-L-Asparaginase, PEG-L-Asparaginase (Enzon - Kyowa Hakko), PEGASPARGASE, PEGLA, Polyethylene Glycol L-Asparaginase, Polyethylene Glycol-L-Asparaginase — per NCIT
Also identified as
- ATC L01XX24 per RXNORM
- NCIT NCIT:C1200 per NCIT
- SCTID 108814000 per RXNORM
- SCTID 416337002 per RXNORM
- UNII 7D96IR0PPM per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| B-cell chronic lymphocytic leukemia | may treat | MEDRT · Public domain (U.S. Government work) |
| Blast phase chronic myelogenous leukemia, BCR-ABL1 positive | may treat | MEDRT · Public domain (U.S. Government work) |
| Non-Hodgkin lymphoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Bone marrow | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Lymphoid system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.